Form 4: Rani Therapeutics Director Amends Stock Option Exercise Price

A director of Rani Therapeutics Holdings, Inc. amended the exercise price of their stock options from $2.84 to $4.11 per share on December 16, 2024.

Summary

• On December 16, 2024, a director of Rani Therapeutics, Imran Mir, amended the exercise price of his stock options.
• The original exercise price of the stock options was $2.84 per share.
• The amended exercise price is $4.11 per share.
• The amendment does not change the expiration dates or vesting schedule of the options.
• The director now holds 101,276 stock options at the new exercise price of $4.11.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of a stock option amendment, with no inherent positive or negative sentiment.

Industry Context

This is a standard SEC Form 4 filing related to changes in beneficial ownership of securities by a company insider. It is common for companies to adjust stock option prices.

Comparison to Industry Standards

• Stock option amendments are a common practice in publicly traded companies, often reflecting changes in the company's valuation or market conditions.
• The adjustment of the exercise price from $2.84 to $4.11 is a specific change for this director's options and does not necessarily reflect a broader trend in the industry.
• Comparable companies in the biotech sector also use stock options as part of their compensation packages, and similar adjustments may occur based on company performance and market conditions.

Stakeholder Impact

• The change in stock option price may have a minor impact on the director's potential future compensation.
• The change does not directly impact other stakeholders such as shareholders, employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, exercise price, Rani Therapeutics, director, amendment, equity